Co-Diagnostics Analyst Ratings
Co-Diagnostics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/13/2023 | 159.43% | HC Wainwright & Co. | $2 → $3 | Maintains | Neutral |
| 08/14/2023 | 72.95% | HC Wainwright & Co. | $3 → $2 | Maintains | Neutral |
| 05/15/2023 | 159.43% | HC Wainwright & Co. | → $3 | Reiterates | Neutral → Neutral |
| 03/20/2023 | 159.43% | HC Wainwright & Co. | $6 → $3 | Downgrades | Buy → Neutral |
| 02/23/2023 | 418.85% | HC Wainwright & Co. | → $6 | Reiterates | → Buy |
| 11/14/2022 | 418.85% | HC Wainwright & Co. | $9 → $6 | Maintains | Buy |
| 08/15/2022 | 678.28% | HC Wainwright & Co. | $12 → $9 | Maintains | Buy |
| 08/12/2022 | 332.38% | Sidoti & Co. | → $5 | Downgrades | Buy → Neutral |
| 05/16/2022 | 937.7% | HC Wainwright & Co. | $15 → $12 | Maintains | Buy |
| 11/12/2021 | 1197.13% | HC Wainwright & Co. | $16 → $15 | Maintains | Buy |
| 03/29/2021 | — | Maxim Group | Downgrades | Buy → Hold | |
| 03/26/2021 | 1283.6% | HC Wainwright & Co. | $30 → $16 | Maintains | Buy |
| 12/15/2020 | 2494.26% | HC Wainwright & Co. | $29 → $30 | Maintains | Buy |
| 11/17/2020 | 2407.78% | HC Wainwright & Co. | $33 → $29 | Maintains | Buy |
| 08/14/2020 | 2753.68% | HC Wainwright & Co. | $35 → $33 | Maintains | Buy |
| 05/20/2020 | 2494.26% | Maxim Group | → $30 | Upgrades | Hold → Buy |
| 05/18/2020 | 2926.63% | HC Wainwright & Co. | $20 → $35 | Reiterates | → Buy |
| 03/03/2020 | — | Maxim Group | Downgrades | Buy → Hold | |
| 02/24/2020 | 245.9% | HC Wainwright & Co. | $2 → $4 | Maintains | Buy |
| 04/09/2019 | 72.95% | Maxim Group | → $2 | Initiates Coverage On | → Buy |
| 03/11/2019 | 72.95% | HC Wainwright & Co. | → $2 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 11/13/2023 | 159.43% | HC Wainwright & Co. | 2 美元 → 3 美元 | 维护 | 中立 |
| 08/14/2023 | 72.95% | HC Wainwright & Co. | 3 美元 → 2 美元 | 维护 | 中立 |
| 05/15/2023 | 159.43% | HC Wainwright & Co. | → 3 美元 | 重申 | 中性 → 中性 |
| 03/20/2023 | 159.43% | HC Wainwright & Co. | 6 美元 → 3 美元 | 降级 | 买入 → 中性 |
| 02/23/2023 | 418.85% | HC Wainwright & Co. | → 6 美元 | 重申 | → 购买 |
| 11/14/2022 | 418.85% | HC Wainwright & Co. | 9 美元 → 6 美元 | 维护 | 买 |
| 08/15/2022 | 678.28% | HC Wainwright & Co. | 12 美元 → 9 美元 | 维护 | 买 |
| 2022 年 12 月 8 日 | 332.38% | Sidoti & Co. | → 5 美元 | 降级 | 买入 → 中性 |
| 05/16/2022 | 937.7% | HC Wainwright & Co. | 15 美元 → 12 美元 | 维护 | 买 |
| 11/12/2021 | 1197.13% | HC Wainwright & Co. | 16 美元 → 15 美元 | 维护 | 买 |
| 03/29/2021 | — | Maxim 集团 | 降级 | 买入 → 持有 | |
| 2021 年 3 月 26 日 | 1283.6% | HC Wainwright & Co. | 30 美元 → 16 美元 | 维护 | 买 |
| 2020 年 12 月 15 日 | 2494.26% | HC Wainwright & Co. | 29 美元 → 30 美元 | 维护 | 买 |
| 2020 年 11 月 17 日 | 2407.78% | HC Wainwright & Co. | 33 美元 → 29 美元 | 维护 | 买 |
| 2020 年 8 月 14 日 | 2753.68% | HC Wainwright & Co. | 35 美元 → 33 美元 | 维护 | 买 |
| 05/20/2020 | 2494.26% | Maxim 集团 | → 30 美元 | 升级 | 持有 → 买入 |
| 2020 年 5 月 18 日 | 2926.63% | HC Wainwright & Co. | 20 美元 → 35 美元 | 重申 | → 购买 |
| 2020 年 3 月 3 日 | — | Maxim 集团 | 降级 | 买入 → 持有 | |
| 2020 年 2 月 24 日 | 245.9% | HC Wainwright & Co. | 2 美元 → 4 美元 | 维护 | 买 |
| 2019 年 9 月 4 日 | 72.95% | Maxim 集团 | → 2 美元 | 启动覆盖范围开启 | → 购买 |
| 2019 年 11 月 3 日 | 72.95% | HC Wainwright & Co. | → 2 美元 | 启动覆盖范围开启 | → 购买 |
What is the target price for Co-Diagnostics (CODX)?
协同诊断 (CODX) 的目标价格是多少？
The latest price target for Co-Diagnostics (NASDAQ: CODX) was reported by HC Wainwright & Co. on November 13, 2023. The analyst firm set a price target for $3.00 expecting CODX to rise to within 12 months (a possible 159.43% upside). 6 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 于2023年11月13日公布了Co-Diagnostics（纳斯达克股票代码：CODX）的最新目标股价。该分析公司将目标股价定为3.00美元，预计CODX将在12个月内升至12个月内（可能上涨159.43％）。去年有6家分析公司公布了评级。
What is the most recent analyst rating for Co-Diagnostics (CODX)?
分析师对协同诊断 (CODX) 的最新评级是多少？
The latest analyst rating for Co-Diagnostics (NASDAQ: CODX) was provided by HC Wainwright & Co., and Co-Diagnostics maintained their neutral rating.
Co-Diagnostics（纳斯达克股票代码：CODX）的最新分析师评级由HC Wainwright & Co. 提供，Co-Diagnostics 维持中性评级。
When is the next analyst rating going to be posted or updated for Co-Diagnostics (CODX)?
Co-Diagnostics (CODX) 的下一个分析师评级何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Co-Diagnostics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Co-Diagnostics was filed on November 13, 2023 so you should expect the next rating to be made available sometime around November 13, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与Co-Diagnostics的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。Co-Diagnostics的最新评级是在2023年11月13日公布的，因此您应该预计下一个评级将在2024年11月13日左右公布。
Is the Analyst Rating Co-Diagnostics (CODX) correct?
分析师评级联合诊断 (CODX) 是否正确？
While ratings are subjective and will change, the latest Co-Diagnostics (CODX) rating was a maintained with a price target of $2.00 to $3.00. The current price Co-Diagnostics (CODX) is trading at is $1.16, which is out of the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但最新的协同诊断（CODX）评级维持不变，目标股价为2.00美元至3.00美元。Co-Diagnostics（CODX）目前的交易价格为1.16美元，超出了分析师的预期区间。